ISA Pharmaceuticals names Nigel Crockett Business Development director
ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management team.
Nigel Crockett has been appointed as the new business development director becoming responsible for the business strategic direction of the company. Nigel has over 20 years’ experience in the pharma-biotech sector and, as the Commercial Director at Astex Therapeutics, Nigel was responsible for more than 13 major collaboration and licensing deals in a period of just four years. During his commercial career to date he has executed over 30 major in- and out-licensing deals and has been involved in the completion of several company acquisitions, for Astex Therapeutics and for Cantab Pharmaceuticals. At the latter company he spent his early career as a researcher developing cervical cancer vaccines, having previously obtained his PhD (Molecular Biology) from Cambridge University in 1989 and a BSc (Chemistry) from the University of Manchester in 1986. Gerard Platenburg, Chief Executive of ISA, commented, “The appointment of Nigel strengthens our senior management team and is a reflection of our strategy to become a global leader in therapeutic SLP-based products. He brings to ISA a wealth of experience, which will greatly enhance our business development efforts.”
ISA Pharmaceuticals is dedicated to fighting cancer and infectious diseases by providing novel ways based on its proprietary SLP® technology to activate and employ the patient’s own immune system. Its most advanced product is a therapeutic vaccine against HPV-induced lesions. The company was founded in 2004 by Aglaia Oncology Fund and has its roots in the ground breaking research performed by the group of internationally renowned tumor immunologist Professor Kees Melief. R&D is performed in close collaboration with the Leiden University Medical Center, the Netherlands. For more information about ISA, please visit www.isa-pharma.com.
Contact details: Gerard Platenburg, CEO, firstname.lastname@example.org